KINICITI

KINICITI is dedicated to empowering partner companies by providing resources, expertise, and capital to accelerate the advancement and adoption of cell and gene therapies. The company is focused on building partnerships that leverage the value from a dynamic scientific and business ecosystem, particularly by investing in non-therapeutic companies that support cell and gene therapy innovation. KINICITI has raised additional capital from Biospring Partners to fund its global platform serving the Cell & Gene Therapy Industry. Furthermore, Welsh, Carson, Anderson & Stowe has committed $250 million in a strategic partnership with KINICITI to invest in companies that support cell and gene therapy innovation. KINICITI’s investment interests include companies with transformational capabilities in areas such as cell engineering, gene-editing, cell sources, process science, scale-up tools, production technologies, and source-to-patient delivery systems. The company employs a flexible investment model aimed at ensuring that companies supporting cell and gene therapeutics have the necessary capital and strategic resources to enable these therapies to reach patients rapidly and reliably.